Skip to search formSkip to main contentSkip to account menu

Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine

Known as: PROSTVAC-F, rFowlpox-PSA(L155)/TRICOM Vaccine 
A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Vaccine approaches for cancer differ from traditional vaccine approaches for infectious disease in tending to focus on clearing… 
2015
2015
Anti-tumor vaccines have demonstrated efficacy in patients with castration-resistant metastatic prostate cancer. One vaccine… 
2014
2014
Significance Because individual cancer patients differ considerably in their clinical benefits from immunotherapies, early… 
Review
2013
Review
2013
Since the approval of sipuleucel-T for men with metastatic castrate resistant prostate cancer in 2010, great strides in the… 
2013
2013
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some patients with cancer, but responses… 
Review
2012
Review
2012
Purpose of review The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate… 
Highly Cited
2011
Highly Cited
2011
The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The… 
Review
2009
Review
2009
Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector as a primary vaccination, followed by… 
Highly Cited
2005
Highly Cited
2005
PurposeBased on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific… 
2005
2005
2504 Background: Vaccine strategies represent a novel therapeutic approach for the treatment of metastatic AIPC. Preclinical and…